These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27842887)

  • 61. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A metabolomics guided exploration of marine natural product chemical space.
    Floros DJ; Jensen PR; Dorrestein PC; Koyama N
    Metabolomics; 2016 Sep; 12(9):. PubMed ID: 28819353
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolomics and its practical value in pharmaceutical industry.
    Wei R
    Curr Drug Metab; 2011 May; 12(4):345-58. PubMed ID: 21395528
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The use of partially porous particle columns for the routine, generic analysis of biological samples for pharmacokinetic studies in drug discovery by reversed-phase ultra-high performance liquid chromatography-tandem mass spectrometry.
    Mallett DN; Ramírez-Molina C
    J Pharm Biomed Anal; 2009 Jan; 49(1):100-7. PubMed ID: 19019615
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.
    Rasmussen HB; Bjerre D; Linnet K; Jürgens G; Dalhoff K; Stefansson H; Hankemeier T; Kaddurah-Daouk R; Taboureau O; Brunak S; Houmann T; Jeppesen P; Pagsberg AK; Plessen K; Dyrborg J; Hansen PR; Hansen PE; Hughes T; Werge T;
    Pharmacogenomics; 2015; 16(6):649-65. PubMed ID: 25896426
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes.
    Nakayama N; Bando Y; Fukuda T; Kawamura T; Nakamura H; Marko-Varga G; Nishimura T
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):3-11. PubMed ID: 26782309
    [TBL] [Abstract][Full Text] [Related]  

  • 67. LC-MS-based metabolomics in the clinical laboratory.
    Becker S; Kortz L; Helmschrodt C; Thiery J; Ceglarek U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():68-75. PubMed ID: 22074957
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer.
    An Z; Chen Y; Zhang R; Song Y; Sun J; He J; Bai J; Dong L; Zhan Q; Abliz Z
    J Proteome Res; 2010 Aug; 9(8):4071-81. PubMed ID: 20560663
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inductively coupled plasma-MS in drug development: bioanalytical aspects and applications.
    van Heuveln F; Meijering H; Wieling J
    Bioanalysis; 2012 Aug; 4(15):1933-65. PubMed ID: 22943623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single-Cell Metabolomics.
    Emara S; Amer S; Ali A; Abouleila Y; Oga A; Masujima T
    Adv Exp Med Biol; 2017; 965():323-343. PubMed ID: 28132186
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Profiling the Oxylipin and Endocannabinoid Metabolome by UPLC-ESI-MS/MS in Human Plasma to Monitor Postprandial Inflammation.
    Gouveia-Figueira S; Späth J; Zivkovic AM; Nording ML
    PLoS One; 2015; 10(7):e0132042. PubMed ID: 26186333
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics.
    Saigusa D; Matsukawa N; Hishinuma E; Koshiba S
    Drug Metab Pharmacokinet; 2021 Apr; 37():100373. PubMed ID: 33631535
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry - dihydrouracil and progesterone in the metabolism of Down syndrome.
    Trivedi DK; Iles RK
    Biomed Chromatogr; 2015 Aug; 29(8):1173-83. PubMed ID: 25545476
    [TBL] [Abstract][Full Text] [Related]  

  • 74. SIMILE enables alignment of tandem mass spectra with statistical significance.
    Treen DGC; Wang M; Xing S; Louie KB; Huan T; Dorrestein PC; Northen TR; Bowen BP
    Nat Commun; 2022 May; 13(1):2510. PubMed ID: 35523965
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clustering of MS
    Depke T; Franke R; Brönstrup M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1071():19-28. PubMed ID: 28642031
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review.
    Roux A; Lison D; Junot C; Heilier JF
    Clin Biochem; 2011 Jan; 44(1):119-35. PubMed ID: 20800591
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New analytical strategies in studying drug metabolism.
    Staack RF; Hopfgartner G
    Anal Bioanal Chem; 2007 Aug; 388(7):1365-80. PubMed ID: 17583803
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combined use of ESI-QqTOF-MS and ESI-QqTOF-MS/MS with mass-spectral library search for qualitative analysis of drugs.
    Pavlic M; Libiseller K; Oberacher H
    Anal Bioanal Chem; 2006 Sep; 386(1):69-82. PubMed ID: 16896628
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening.
    Whalen K; Gobey J; Janiszewski J
    Rapid Commun Mass Spectrom; 2006; 20(10):1497-503. PubMed ID: 16628559
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bioanalytical hydrophilic interaction chromatography: recent challenges, solutions and applications.
    Xu RN; Rieser MJ; El-Shourbagy TA
    Bioanalysis; 2009 Apr; 1(1):239-53. PubMed ID: 21083199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.